OBJECTIVE: The CXCR4 antagonist AMD3100 mobilizes hematopoietic stem/progenitor cells (HSPC) in several species. Few data are available on the biology of HSPC mobilized with AMD3100 as single agent. To further study the kinetics and properties of AMD3100-mobilized HSPC, and to explore the size of mobilizable pools of HSPC targeted by AMD3100, we studied the effect of a continuous infusion scheme with saturating doses of AMD3100 [AMDi]. MATERIALS AND METHODS: Using established procedures, we evaluated mice mobilized with AMD3100, or those transplanted with AMD3100-mobilized HSPC. RESULTS: Relative to single-bolus AMD3100 [AMDb], the number of circulating CFU-C or CRU was dramatically higher after [AMDi]. During [AMDi], circulating CFU-C accumulated slowly, but after its discontinuation, CFU-C disappeared rapidly. Compared to bone marrow (BM)-c-kit(+) cells, AMD3100-mobilized (AMDb or AMDi) c-kit(+) cells showed reduced expression of several cytoadhesion molecules, similar to granulocyte colony-stimulating factor-mobilized c-kit(+) cells. In contrast to the latter, expression of CXCR4 and CD26 were not reduced on AMD3100-mobilized c-kit(+) cells. BM homing of [AMDi]-mobilized CFU-C was >50% increased over normal BM-CFU-C. Hematopoietic recovery after transplantation of [AMDi]-mobilized peripheral blood was comparable to that of continuous infusion granulocyte colony-stimulating factor-mobilized peripheral blood. AMD3100-mobilized HSPC were predominantly in G(0), and partial bromodeoxyuridine-labeling experiments documented underrepresentation of labeled cells (<5%) among [AMDb]-mobilized c-kit(+) cells, suggesting that cycling cells in BM, or those that recently completed cell cycle, are not targeted for mobilization by AMD3100. CONCLUSIONS: Our data demonstrate that [AMDi] is an efficacious mobilization scheme fully supporting transplantation demands and expands previous knowledge about properties and size of AMD3100-sensitive BM-HSPC pools.
OBJECTIVE: The CXCR4 antagonist AMD3100 mobilizes hematopoietic stem/progenitor cells (HSPC) in several species. Few data are available on the biology of HSPC mobilized with AMD3100 as single agent. To further study the kinetics and properties of AMD3100-mobilized HSPC, and to explore the size of mobilizable pools of HSPC targeted by AMD3100, we studied the effect of a continuous infusion scheme with saturating doses of AMD3100 [AMDi]. MATERIALS AND METHODS: Using established procedures, we evaluated mice mobilized with AMD3100, or those transplanted with AMD3100-mobilized HSPC. RESULTS: Relative to single-bolus AMD3100 [AMDb], the number of circulating CFU-C or CRU was dramatically higher after [AMDi]. During [AMDi], circulating CFU-C accumulated slowly, but after its discontinuation, CFU-C disappeared rapidly. Compared to bone marrow (BM)-c-kit(+) cells, AMD3100-mobilized (AMDb or AMDi) c-kit(+) cells showed reduced expression of several cytoadhesion molecules, similar to granulocyte colony-stimulating factor-mobilized c-kit(+) cells. In contrast to the latter, expression of CXCR4 and CD26 were not reduced on AMD3100-mobilized c-kit(+) cells. BM homing of [AMDi]-mobilized CFU-C was >50% increased over normal BM-CFU-C. Hematopoietic recovery after transplantation of [AMDi]-mobilized peripheral blood was comparable to that of continuous infusion granulocyte colony-stimulating factor-mobilized peripheral blood. AMD3100-mobilized HSPC were predominantly in G(0), and partial bromodeoxyuridine-labeling experiments documented underrepresentation of labeled cells (<5%) among [AMDb]-mobilized c-kit(+) cells, suggesting that cycling cells in BM, or those that recently completed cell cycle, are not targeted for mobilization by AMD3100. CONCLUSIONS: Our data demonstrate that [AMDi] is an efficacious mobilization scheme fully supporting transplantation demands and expands previous knowledge about properties and size of AMD3100-sensitive BM-HSPC pools.
Authors: H Shen; T Cheng; I Olszak; E Garcia-Zepeda; Z Lu; S Herrmann; R Fallon; A D Luster; D T Scadden Journal: J Immunol Date: 2001-04-15 Impact factor: 5.422
Authors: D Blaise; M Kuentz; C Fortanier; J H Bourhis; N Milpied; L Sutton; J P Jouet; M Attal; P Bordigoni; J Y Cahn; J M Boiron; M P Schuller; J P Moatti; M Michallet Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: H Openshaw; O Stuve; J P Antel; R Nash; B T Lund; L P Weiner; A Kashyap; P McSweeney; S Forman Journal: Neurology Date: 2000-06-13 Impact factor: 9.910
Authors: Craig L Semerad; Matthew J Christopher; Fulu Liu; Brenton Short; Paul J Simmons; Ingrid Winkler; Jean-Pierre Levesque; Jean Chappel; F Patrick Ross; Daniel C Link Journal: Blood Date: 2005-07-21 Impact factor: 22.113
Authors: Darja Karpova; Julie K Ritchey; Matthew S Holt; Grazia Abou-Ezzi; Darlene Monlish; Lena Batoon; Susan Millard; Gabriele Spohn; Eliza Wiercinska; Ezhil Chendamarai; Wei Yang; Stephanie Christ; Leah Gehrs; Laura G Schuettpelz; Klaus Dembowsky; Allison R Pettit; Michael P Rettig; Halvard Bonig; John F DiPersio Journal: Blood Date: 2017-04-11 Impact factor: 22.113
Authors: Yongfeng Zhao; Lisa Detering; Deborah Sultan; Matthew L Cooper; Meng You; Sangho Cho; Stephanie L Meier; Hannah Luehmann; Guorong Sun; Michael Rettig; Farrokh Dehdashti; Karen L Wooley; John F DiPersio; Yongjian Liu Journal: ACS Nano Date: 2016-05-18 Impact factor: 15.881
Authors: Chang Li; Kevin A Goncalves; Tamás Raskó; Amit Pande; Sucheol Gil; Zhinan Liu; Zsuzsanna Izsvák; Thalia Papayannopoulou; John C Davis; Hans-Peter Kiem; André Lieber Journal: Blood Adv Date: 2021-03-09
Authors: Kent W Christopherson; Robin R Frank; Sucheta Jagan; Laura A Paganessi; Stephanie A Gregory; Henry C Fung Journal: Exp Hematol Date: 2012-07-27 Impact factor: 3.084